Has Danny Benmoshe, MD received payments from drug or device companies?

Yes. Drug and device makers reported $268,663 in general payments to Danny Benmoshe, MD across 1,076 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Danny Benmoshe, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Danny Benmoshe, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Danny Benmoshe, MD

Neurology · Santa Monica, CANPI 1336330141

Payments from drug & device makers

$268,663in general payments, 2019–2025

Across 1,076 payments — averaging $249.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eisai Inc.$83K
AbbVie$78K
Lilly USA, LLC$70K
Biohaven Pharmaceuticals, Inc.$20K
Biogen$4K
Biohaven Pharmaceutical Holding Company Ltd.$2K
plus $11K from 54 others

What the payments were for

Consulting fees$14,5105%
Speaking & faculty fees$202,49775%
Travel & lodging$26,65110%
Food & beverage$23,1409%
Education$1,5391%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eisai Inc.	156	$83,142
AbbVie(2 entities)	236	$78,037
Lilly USA, LLC	114	$70,043
Biohaven Pharmaceuticals, Inc.	38	$19,673
Biogen	56	$4,105
Biohaven Pharmaceutical Holding Company Ltd.	8	$2,291
Amgen(2 entities)	46	$1,225
Lundbeck LLC	35	$992
Upsher-smith Laboratories LLC	53	$813
Pfizer	25	$700
Teva Pharmaceuticals USA, Inc.	25	$560
MDD US Operations, LLC	39	$526
Acorda Therapeutics, Inc	16	$369
Neurelis, Inc.	9	$356
Impel Pharmaceuticals Inc.	11	$301
Acadia Pharmaceuticals Inc	13	$293
Amneal Pharmaceuticals LLC	15	$269
Mallinckrodt Hospital Products Inc.	8	$253
UCB, Inc.	13	$250
Axsome Therapeutics, Inc.	5	$244
SK Life Science, Inc.	9	$232
Neurocrine Biosciences, Inc.	10	$223
Novartis	8	$215
Tanabe Pharma America, Inc.	9	$215
Forte Bio-pharma LLC	9	$209
Genentech USA, Inc.	4	$192
Jazz Pharmaceuticals Inc.	2	$161
AstraZeneca	6	$153
Merz Pharmaceuticals, LLC	4	$151
Otsuka America Pharmaceutical, Inc.	6	$150
EMD Serono, Inc.	2	$149
Abbott	6	$140
Alnylam Pharmaceuticals Inc.	7	$136
Alkermes, Inc.	1	$126
Kyowa Kirin, Inc.	5	$120
Akcea Therapeutics, Inc.	1	$120
Promius Pharma LLC	4	$114
C2n Diagnostics, LLC	2	$102
Avanir Pharmaceuticals, Inc.	4	$85
GE HealthCare	3	$81
Ipsen Biopharmaceuticals, Inc	3	$74
Argenx US, Inc.	3	$69
Supernus Pharmaceuticals, Inc.	3	$68
Takeda Pharmaceuticals U.S.A., Inc.	3	$65
Johnson & Johnson	2	$58
Zyla Life Sciences, Inc.	3	$52
Boston Scientific	2	$51
Catalyst Pharmaceuticals, Inc.	2	$47
Tersera Therapeutics LLC	2	$46
Assertio Therapeutics, Inc.	2	$45
Impel Pharmaceuticals LLC	2	$43
TG Therapeutics, Inc.	2	$42
Harmony Biosciences LLC	1	$41
Neuronetics, Inc.	1	$36
GRT US Holding, Inc.	2	$36
Cycle Pharmaceuticals Inc	1	$30
ANI Pharmaceuticals, Inc.	1	$30
Life Molecular Imaging Ltd	1	$29
Tonix Medicines, Inc.	1	$28
Cala Health, Inc.	1	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Leqembi$80,817
UBRELVY$66,298
KISUNLA$23,111
NURTEC ODT$21,366
QULIPTA$17,963
LYBALVI$503
VRAYLAR$367
TYSABRI$300
TECFIDERA$251
OCREVUS$146
VYEPTI$125
VALTOCO$123
Auvelity$120
TEGSEDI$120
Enbrel$114
Trudhesa$104

How this compares

$268,663 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California →

Medicare billing

Part B allowed, 2024

$497,264

Medicare patients

416

Services billed

76,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Memantine Hcl ErMemantine Hcl	55	$6,777
Rivastigmine	19	$5,398
Galantamine ErGalantamine Hbr	48	$3,454
Memantine Hcl	76	$2,920
Carbidopa-LevodopaCarbidopa/Levodopa	103	$2,053
Duloxetine Hcl	89	$1,774
Donepezil Hcl	140	$1,672
Gabapentin	143	$1,524
Quetiapine Fumarate	51	$1,353
Baclofen	73	$1,347
Levetiracetam	30	$1,125
Pregabalin	42	$1,046
Rasagiline Mesylate	15	$887
Escitalopram Oxalate	42	$416
Levetiracetam ErLevetiracetam	16	$398

Paid to pharmacies, not to this prescriber.

Other neurology in Santa Monica

David KudrowSanta Monica$12.8M
Naveed WagleSanta Monica$1.8M
Santosh KesariSanta Monica$1.6M
Timothy CloughesyLos Angeles$33.1M
Jack FlorinFullerton$13M
John Ravitsla Jolla$8.4M
Perminder BhatiaFresno$8.3M
Perry ShiehLos Angeles$8.2M
Benjamin FrishbergCarlsbad$8.2M
Bruce CreeSan Francisco$8M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →